: Artery Network
Artery Network learned for the first time that Huiyan Biotechnology, a domestic protein purification technology representative company, recently announced the completion of a tens of millions of RMB A round of financing, exclusively invested by Shanghai Green River Investment, and the financing proceeds are mainly used to construct a 10,000L agar Sugar microsphere production line to meet the rapidly growing demand of domestic protein separation and purification fillers in the biopharmaceutical industry.
It is reported that the production line is composed of two sets of 5000L reactors, which can produce 5000L agarose microspheres in a single batch, and the maximum annual output can reach 50000L. Huiyan's self-developed domestic protein purification technology breaks the monopoly of imported fillers and reduces the domestic biopharmaceutical industry's dependence on imported fillers.
Huiyan Biotechnology was established in 2013. It is one of the few domestic companies that master the core formation technology of agarose microspheres. Its product lines include molecular sieves, ion exchange, affinity, hydrophobicity, and more than 100 protein separation and purification fillers. . Among them, Huiyan Biotech's 1000L microsphere reactor has been continuously produced for more than 4 years. The quality, yield, and batch stability of microspheres are among the top in China, and it has achieved domestic substitution in the production lines of many biopharmaceutical companies.
masters the core process of "balling" to help domestic purification replace
agarose microspheres are made from imported agarose powder through inverse emulsion polymerization. Huiyan Biotechnology has mastered agarose, dextran and cellulose. Microsphere formation process and microsphere surface modification technology. This core "ball formation" process helps Huiyan Biosciences independently develop agarose microspheres in particle size distribution, functional capacity, non-specific adsorption, and service life. The internal control and external control parameters meet the standards of imported products, and many products can achieve 100% domestic substitution without changing the production process.
At present, Huiyan Biotech's agarose microspheres have covered more than 90% of imported products. Application cases include human vaccines, blood products, antibody drugs, gene therapy viral vectors, recombinant protein drugs, IVD diagnostic reagents, and animal vaccines.
In recent years, there have been more and more innovative protein drugs in China. Due to their special physical and chemical structural differences, conventional fillers cannot meet the purification process requirements. Based on the various properties of proteins, Huiyan Biosciences has exclusively developed a variety of innovative agarose microspheres to meet the purification requirements of new protein drugs by directional adjustment of the material, particle size, pore size and strength of the microspheres.
Among them, in the field of animal vaccines, a high-recovery microsphere product developed by Huiyan Biotechnology can increase the recovery rate of VLP from 60% of conventional products to 80%, and at the same time increase the production efficiency by more than 10 times, Significantly reduces the cost of vaccine purification, improves the quality of animal vaccines, and helps domestic animal vaccine companies to enter the "purification era".
Similarly, for PEG-modified long-acting recombinant protein drugs, Huiyan Biology has also developed a large-pore microsphere product that can effectively remove free PEG and improve protein recovery. With the vigorous development of domestic biopharmaceuticals, Huiyan Bio will work hand in hand with pharmaceutical companies to solve the separation and purification problems of domestic pharmaceutical companies from multiple perspectives such as microspheres, ligands, and technology, and help pharmaceutical companies to efficiently develop and produce. As the exclusive investor of Huiyan Biotech’s Series A financing, Shanghai Green River Investment recognized: “Agarose chromatography packing is a key consumable in the downstream separation and purification process of biopharmaceuticals. It has been monopolized by imported products for a long time. With the rise of the macromolecule market, there are also some market opportunities for domestically produced chromatography fillers. Huiyan Biotech's product development and market development capabilities have shown a competitive advantage in the market, and it has a deep layout in the fields of animal vaccines, human vaccines and recombinant proteins. In addition to the strong execution of the team, we believe that in the development of the domestic biomacromolecule market, Huiyan Biotech can help domestic pharmaceutical companies to get rid of the situation of highly dependent on imported fillers and consumables, and establish a domestically independent production line."
With the approval of Green River Investment and the completion of the A round of financing, the founder of Huiyan Biotech, Yi Guojun, responded: “Thanks to Shanghai Green River Investment for its recognition and support of Huiyan Biotechnology. After 7 years of accumulation and precipitation, Huiyan Biotechnology The technology and talent reserves have been prepared. This round of financing is a new start for Huiyan Bio. The 10,000L production line is also a new starting point for Huiyan Bio. The demand for protein purification microspheres in the biopharmaceutical field will continue to grow rapidly. The replacement is about to explode, Huiyan Biological Association will continue to increase R&D investment and launch more overall solutions for the separation and purification of biological products to help domesticBiopharmaceutical companies reduce costs and increase efficiency. "Z1z
About Shanghai Green River Investment
Green River Investment, founded in 2007, is an investment institution specializing in early-stage venture capital. Green River Investment has adhered to the core concept of "value, growth" at the beginning of its establishment, and upholds "long-term company The determination to "grow", with a professional and keen eye, not blindly chasing the outlets, make advance layout of emerging industries, firmly believe in the belief of "technology creates value", actively integrate into the national strategy, and help the development of national technology industries. Up to now, Green River Investment The overall scale of its management funds has exceeded RMB 3 billion, and it has invested in more than 50 innovative companies to provide capital and operational support for high-quality startup projects. The main investment directions are biomedical, new energy, new materials, and high-end manufacturing.
